K2M received right to treat revolutionary injectable polymer technology for spinal disorders





K2M, Inc., a spinal device company, announced that it has entered into an agreement with Promethean Surgical Devices, Inc. (PSD) for the worldwide exclusive rights for all spinal applications of a breakthrough injectable polymer technology which may be used to address numerous spinal disorders.

K2M, Inc., a spinal device company, announced that it has entered into an agreement with Promethean Surgical Devices, Inc. (PSD) for the worldwide exclusive rights for all spinal applications of a breakthrough injectable polymer technology which may be used to address numerous spinal disorders.

Eric Major, K2M’s President and CEO said, Acquiring this injectable polymer technology signals the beginning of a new phase in the growth of K2M and our commitment to the development of market leading technologies.

Jeff Wilson, PSD’s President and CEO says, It has been our ongoing belief that the material we have developed at PSD is ideal for spinal applications. With K2M’s expertise in the spinal market and its team of world renowned spinal surgeons, we believe we have found the ideal partner to provide focus for the R&D and commercialization of products utilizing this unique polymer technology.